Theoretical model demonstrates enhanced optical sensitivity with MXene in cancer detection, implying improved screening potential.
Early-stage cancer screening benefits from optical transducers capable of reading minute refractive-index deviations in biofluids. This work models a surface-plasmon-resonance (SPR) biosensor that stacks copper, silicon nitride, and MXene in Kretschmann geometry and evaluates its response to six tumour-related refractive-index increments (Δn = 0.014–0.024 RIU). Transfer-matrix calculations guide a layer-by-layer optimisation: 40 nm Cu, 7 nm Si₃N₄, and two MXene sheets form the best-balanced configuration (Sys₃), while a single MXene layer on 45 nm Cu (Sys₄) offers an alternative with lower optical loss. The optimised MXene sensors raise angular sensitivity to 254° RIU −1 (Sys₃) and 312° RIU −1 (Sys₄) for the breast-T2 model, more than doubling the response of a dielectric-only stack and approaching values reported for multi-metal reference designs. Quality factors range from 48 to 58 RIU −1 in Sys₄ and 30 to 35 RIU −1 in Sys₃, corresponding detection limits fall near 2 × 10 −5 RIU, sufficient to resolve the smallest Δn in the cancer panel. Optical loss remains below 9% in Sys₃ and under 8% in Sys₄, preserving reflected-intensity contrast for angle tracking. These results indicate that a copper platform augmented with sub-nanometre MXene and a thin Si₃N₄ spacer can match state-of-the-art sensitivity while relying on a single plasmonic metal and low-temperature fabrication. The study is purely theoretical and uses bulk refractive-index shifts as the sensing mechanism, future work should address surface chemistry, fabrication tolerances, and clinical validation.
No takes yet. Share an insight, caveat, or question.
Tene et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: